The Mumbai-based firm expects a quick recovery in FY27, and is on track to achieve its target of becoming a $2-billion company with 25% Ebitda (earnings before interest, taxes, depreciation, and amortization) margins by FY30, chairperson Nandini Piramal told Mint.
Piramal Pharma CDMO growth hit by US policy jitters; recovery seen in FY27
Related Posts
Hindi ‘imposition’ row: Maharashtra government cancels 3-language policy resolution; oppn exults over rollback
The Maharashtra government has withdrawn its order implementing the three-language policy following opposition protests against the perceived imposition of Hindi. Chief Minister Devendra Fadnavis announced the decision and the formation…
Read moreAC trouble: Air India Tokyo-Delhi flight safely diverts to Kolkata
On June 29, 2025, Air India flight AI357, en route from Tokyo Haneda to Delhi, made a precautionary diversion to Kolkata due to persistent air-conditioning issues causing uncomfortably warm cabin…
Read more